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Abstract 
Background: We report on the activity of anthracycline-based and high-dose prolonged-infusion ifosfamide chemo-
therapy in a retrospective series of patients affected by advanced myxofibrosarcoma treated at Istituto Nazionale 
Tumori in Milan, Italy, and within the Italian Rare Cancer Network (RTR).
Methods: Advanced myxofibrosarcoma patients treated with anthracycline + ifosfamide and high-dose prolonged-
infusion ifosfamide as a single agent from November 2001 to December 2016 were retrospectively reviewed. All 
pathological diagnosis were centrally reviewed by at least two expert pathologists. Response was evaluated by 
RECIST, and survival functions were computed.
Results: Among 34 advanced myxofibrosarcoma patients, 13 were treated with front-line anthracycline + ifosfamide 
chemotherapy (male/female = 6/7, median age 54 years, range 33–72). Overall best response was: 4 partial responses, 
3 stable diseases and 6 progressive diseases, with a median progression-free survival of 4 months. Twenty-eight 
patients received second/further line high-dose prolonged-infusion ifosfamide (male/female = 17/11, median age 
55 years, range 27–75 years). We observed 10 partial responses, 4 stable diseases and 14 progressive diseases, with a 
median progression-free survival of 4 months. Median overall survival was 12 months.
Conclusions: This retrospective analysis suggests that the combination of anthracyclines and ifosfamide is active 
in myxofibrosarcoma. In patients already treated with a combination of anthracyclines and ifosfamide, high-dose 
prolonged-infusion ifosfamide showed activity as well.
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Background
Myxofibrosarcoma is a rare soft tissue sarcoma (STS) 
with an estimated incidence <0.1/100.000/years [1]. His-
torically, it was first described in 1977 as a part of the 
spectrum of myxoid fibroblastic malignancies [2, 3]. It 
was finally included in the WHO classification in 2002 as 
a distinct entity with unique clinicopathological charac-
teristics and cytoarchitectural features [4].
Myxofibrosarcoma is more common in elderly patients 
and it is mainly located to the extremities, especially 
lower limbs, but it can arise in the trunk and in head and 
neck region [5–7]. Since a presentation in the abdominal 
cavity or in the retroperitoneum is extremely rare, a dif-
ferential diagnosis between dedifferentiated liposarcoma 
and myxofibrosarcoma should be always considered [8–
10]. In comparison to the other soft tissue sarcoma types, 
myxofibrosarcoma exhibits an overall better prognosis 
[10–13], with an overall survival (OS) of approximatively 
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70% and an overall risk of metastases between 20 and 
25% in high-grade variants [10–19]. However, myxofibro-
sarcoma tends to have a remarkable rate of local recur-
rences compared to other soft tissue sarcomas, reported 
between 20 and 75% [2, 5, 6, 10, 12, 16].
Surgery alone or in combination with radiotherapy 
is the main treatment for localized disease [10, 12], and 
medical treatment is used in the advance disease. The 
combination of anthracyclines and ifosfamide as front-
line therapy of advanced soft tissue sarcomas is asso-
ciated with response rates of 20–30% in previously 
untreated patients. This percentage drops to 10% in sec-
ond line. However, this reflects the whole group of soft 
tissue sarcomas, which make up a heterogeneous disease 
with discrepant chemosensitivity across the histological 
subtypes. For example, angiosarcoma or myxoid liposar-
coma have been observed to be responsive to chemother-
apy, while other subgroups are poorly responsive [20]. In 
the subgroup of myxofibrosarcomas, the precise role of 
chemotherapy remains undefined and no prospective tri-
als or retrospective analyses are available [21].
Therefore, we carried out this retrospective study on a 
series of patients affected by advanced myxofibrosarcoma 
treated with chemotherapy at the Istituto Nazionale 
Tumori, Milano, Italy, and within the Italian Rare Cancer 
Network, a collaborative network sharing clinical cases 
and data of rare cancers in Italy.
Methods
Thirty-four patients affected by advanced myxofibrosar-
coma, consecutively treated with chemotherapy between 
November 2001 and December 2016 at Fondazione 
IRCCS Istituto Nazionale Tumori, Milan, Italy, and within 
the Italian Rare Cancer Network, were retrospectively 
identified. We retrieved a subgroup of 13 patients treated 
with front-line anthracycline + ifosfamide chemotherapy 
and a subgroup of 28 patients treated with second/fur-
ther line high-dose prolonged-infusion ifosfamide.
Pathological diagnosis was centrally reviewed by at 
least two expert pathologists in all the cases, following 
the most recent updated criteria [4].
Data regarding clinical and histopathological char-
acteristics, staging, surgical and systemic treatment 
and survival were collected. The clinical records were 
reviewed and collected in one institutional database and 
a descriptive analysis was performed. Data on chemo-
therapy tolerability and adverse effects were recorded. 
Response to chemotherapy was evaluated with Response 
Evaluation Criteria in Solid Tumours (RECIST) applied 
to CT and/or MRI scans performed periodically (usually 
every 2–3 months) [22].
This retrospective analysis was approved by the Institu-
tional Ethics Committee of our Institution.
Treatment
When an anthracycline was used in combination 
with ifosfamide, the regimen was epirubicin 105  mg/
sqm  +  ifosfamide 9000  mg/sqm, i.v., in 3  days every 
3  weeks, in association with equidose MESNA, and 
antiemetics. Prophylactic granulocyte colony stimulat-
ing factors were given. High-dose ifosfamide (HDIFX) 
was administered as a single agent, at the daily dose of 
1  g/sqm (total dose of 14  g/sqm per cycle), as a 14-day 
continuous infusion with equidose MESNA, through two 
portable infusional devices lasting 7  days each. HDIFX 
regimen was administered every 4  weeks (2  weeks of 
infusion followed by 2 weeks off).
Statistical analysis
Progression-free Survival (PFS) and Overall Survival 
(OS) were estimated with Kaplan–Meier method [23]. 
Failure for PFS were death or progressive disease accord-
ing to RECIST. Failure for OS was death due to any 
cause. Patients alive were censored at the time of the last 
contact.
Results
Anthracycline + ifosfamide chemotherapy
Thirteen patients affected by advanced myxofibrosar-
coma were treated with front-line anthracycline +  ifos-
famide chemotherapy. Patient characteristics are shown 
in Table 1. Female patients were prevalent (female/male 
7/6); median age at the time of the operation was 54 years 
(range 33–72 years).
All patients treated were assessable for response. 
Median number of chemotherapy cycles was 3 (range 
2–6). The best response according to RECIST was: par-
tial response (PR) in 4/13 cases (31%, 95% CI 0.09–0.61), 
stable disease (SD) in 3/13 (23%, 95% CI 0.05-0.53), pro-
gressive disease (PD) in 6/13 (46%, 95% CI 0.19–0.74) 
cases. Responses were confirmed at 3  months. Median 
PFS was 4 months, with 30% of patients progression-free 
at 6  months (Fig.  1a). Median OS was 12  months, with 
12 patients dead and one patient alive at the time of this 
analysis (Fig. 1b).
Two patients interrupted their treatment for febrile 
neutropenia after 3 cycles of chemotherapy. No toxic 
deaths or any unexpected major toxicities were reported.
High‑dose ifosfamide chemotherapy
Twenty-eight patients received second/further HDIFX. 
Fourteen patients received epirubicin and ifosfamide in 
the adjuvant setting, 9/28 patients were pretreated with 
first line epirubicin and ifosfamide chemotherapy com-
bination and 5/28 were pretreated with other regimens 
(2/5 epirubicin alone, 1/5 dacarbazine, 1/5 docetaxel, 
1/5 gemcitabine). Patient characteristics are detailed 
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in Table  2. Male patients were prevalent (male/female 
17/11); median age at the time of the treatment was 
55 years (range 27–75 years). Median number of HDIFX 
cycles was 3 (range 2–8).
All patients treated with HDIFX were evaluable for 
response. The best response was: PR in 10/28 (36%, 95% 
CI 0.18–0.55), SD in 4/28 (14%, 95% CI 0.04–0.32) and 
PD in 14/28 (50%, 95% CI 0.30–0.69). Among patients 
pretreated with first line epirubicin–ifosfamide, we 
observed 4/9 PD (44%), 3/9 PR (33%), 2/9 SD (23%); all 
patients responding to second line HDIFX had had a 
PR to first-line epirubicin–ifosfamide. Median PFS was 
4 months (Fig. 2a). Median OS was 12 months (Fig. 2b), 
with 27 patients dead and one patient alive at the time of 
this analysis.
No febrile neutropenia and renal failure were observed, 
as well as no toxic deaths or any other unexpected major 
toxicities.
Figure  3 shows a pathological partial response to 
HDIFX.
Table 1 Patients treated with front-line anthracycline + ifosfamide chemotherapy: clinical characteristics and response 
evaluation
M male, F female, CT chemotherapy, PR partial response, SD stable disease, PD progressive disease
Patients ID Gender Age at time of diagno‑
sis (years)
Myxofibrosarcoma 
grade
Site of primary 
tumour
Site of relapse at time 
of CT
Response evalua‑
tion criteria in solid 
tumours (RECIST) 
evaluation
1 M 53 2 Left thigh Lung PR
2 F 72 2 Right arm Right arm SD
3 M 71 3 Thoracic wall Lung PD
4 F 33 3 Abdomen Lung and abdomen PR
5 F 48 1 Left thigh Left thigh SD
6 F 64 1 Scalp Scalp PR
7 M 55 2 Thoracic wall Lung PD
8 F 44 3 Right thigh Right thigh PD
9 F 51 3 Left thigh Lung SD
10 M 64 2 Abdomen Lung PD
11 M 64 2 Left thigh Lung PD
12 F 33 3 Left thigh Lung and abdomen PD
13 M 48 2 Right thigh Lung PR
Fig. 1 Survival functions for patients treated with front line anthracycline + ifosfamide chemotherapy (13 patients). a PFS (median 4 months). b OS 
(median 12 months)
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Discussion
In a retrospective study on a series of 34 consecu-
tive patients with progressing advanced myxofibrosar-
coma treated with chemotherapy on a 15-year span, we 
observed a 30% PR rate, with a median PFS of 4 months 
with two chemotherapy regimens commonly used in 
other soft tissue sarcomas. In our series, the patients 
were relatively young, and the retrospectivity of the anal-
ysis makes it hard to transpose data on toxicity of these 
two regimens to the general population.
The benefit of multi-agent compared to single 
agent  anthracycline-based first line chemotherapy for 
advanced soft tissue sarcomas remains controversial. In 
the biggest randomized prospective trial, the combination 
of doxorubicin and ifosfamide was associated with higher 
response rates, but a non-significant overall survival 
benefit [24]. However, upfront combination chemother-
apy may be of benefit, even considering the increased 
toxicity, for selected patients, e.g. those with a high 
tumor burden requiring a prompt tumor shrinkage or 
those with a fast-growing disease, in need of obtaining a 
response. In terms of responses to anthracycline and ifos-
famide, our results point to an antitumor activity similar 
to advanced soft tissue sarcomas in general [24]. However, 
PFS was markedly low in our series. The limited number 
of patients makes it difficult to speculate on this.
HDIFX is often used as a salvage regimen in syno-
vial sarcoma and dedifferentiated liposarcoma, even in 
patients previously treated with standard-dose ifosfamide 
[25–29]. Furthermore, if compared with the classic ifos-
famide schedule, the administration in the external port-
able device in a prolonged 14-days continuous infusion 
Table 2 Patients treated with second/further-line HDIFX chemotherapy: clinical characteristics and response evaluation
M male, F female, PR partial response, SD stable disease, PD progressive disease
Patients ID Gender Age at time of diagno‑
sis (years)
Myxofibrosarcoma 
grade
Site of primary 
tumour
Site of relapse at time 
of CT
Response evalua‑
tion criteria in solid 
tumours (RECIST) 
evaluation
1 F 62 3 Groin Abdomen PD
2 F 43 3 Right arm Lung PD
3 M 71 2 Left thigh Lung PR
4 M 54 2 Left thigh Lung PR
5 F 72 2 Right arm Local relapse SD
6 M 46 3 Thoracic wall Local relapse RC
7 F 60 3 Right arm Lung PD
8 M 74 2 Left thigh Lung PD
9 M 57 1 Groin Local relapse PR
10 F 33 3 Abdomen Lung and abdomen PR
11 M 34 3 Right thigh Lung PD
12 M 71 3 Right arm Lung PR
13 M 70 1 sex cord Local relapse PR
14 F 48 1 Left thigh Local relapse SD
15 M 51 2 Left thigh Lung PD
16 F 27 2 Abdomen Abdomen SD
17 M 67 1 Left thigh Local relapse PD
18 M 56 2 Thoracic wall Lung PD
19 F 44 3 Right thigh Local relapse PD
20 M 51 3 Left leg Lung PR
21 M 64 2 Abdomen Lung PD
22 F 75 2 Right arm Local relapse PR
23 M 50 1 Right thigh Local relapse PR
24 M 65 2 Left thigh Lung PD
25 M 58 3 Left arm Lung PD
26 F 33 3 Left thigh Lung and abdomen PD
27 F 50 1 Thoracic wall Lung and abdomen SD
28 M 51 3 Left thigh Lung PD
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shows an excellent tolerability. Main toxicities are repre-
sented by mild to moderate nausea and vomiting, while 
myelosuppression, neurotoxicity and acute kidney failure 
are infrequent.
In our series, the anti-tumor activity of HDIFX as sec-
ond/further chemotherapy line in myxofibrosarcoma 
was apparently higher than in other soft tissue sarcomas 
[26–30].
Among 28 patients treated with HDIFX in second/
further line, the PR rate was 36% and median PFS was 
4 months. We reported a similar PR rate for continuous-
infusion HDIFX in well differentiated/dedifferentiated 
liposarcomas [25]. Nine patients were pretreated with first-
line epirubicin–ifosfamide and we observed 4 PR (31% 
RECIST PR) out of 13 patients evaluable for response. 
Thus, high-dose ifosfamide was still active in patients pre-
treated with anthracyclines and standard-dose ifosfamide. 
Again, however, median PFS was low. The previous expo-
sure to ifosfamide may, in part, explain these results.
In advanced soft tissue sarcomas, standard chemo-
therapy is based on anthracyclines as the first-line treat-
ment and the sequencing of second-line, third-line and 
fourth-line treatments remains open to debate [13, 31, 
32]. Histological diagnosis can help guide the sequence 
of treatments [32]. Indeed, a histology-driven choice is 
feasible in some histologies (e.g., paclitaxel for angiosar-
coma, gemcitabine for leiomyosarcoma, trabectedin for 
myxoid liposarcoma, etc.). In this perspective, the rea-
sonably interesting PR rate seen with continuous-infu-
sion HDIFX may be of interest.
Conclusions
This was a retrospective analysis in a relatively young 
small population of patients over a 15-year span. How-
ever, among soft tissue sarcomas, myxofibrosarcoma 
represents a rare subtype. No data are reported so far 
on the activity of chemotherapy and no prospective 
neither retrospective studies focusing on its medical 
Fig. 2 Survival functions for patients treated with continuous infusion HDIFX (28 patients). a PFS (median 4 months). b OS (median 12 months)
Fig. 3 On haematoxylin and eosin staining, a pathologic partial response in a patient treated with six cycles of high-dose ifosfamide. a A thoracic 
wall metastasis from a myxofibrosarcoma arising from the thoracic wall at baseline. b In high power and c the pathologic partial response after 
6 months of treatment with high-dose ifosfamide with areas of necrosis included both vascular and avascular pattern and vital areas
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treatment are available. Obviously, it is difficult to con-
ceive prospective studies in such a rare subtype. In this 
sense, this report adds some information which may 
assist the clinicians in the choice of regimens. However, 
the low PFS implies that we are in need for new thera-
pies for such a histology, when a medical treatment is 
required.
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